Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonggi Choi

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
Journal of Hepatology|June 1, 2022
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resectionSun Yoo, Ji Yoon Kim, Young-Suk Lim, et al.
Journal of Cardiovascular Pharmacology|October 10, 2017
Risks Versus Benefits of Anticoagulation for Atrial Fibrillation in Cirrhotic PatientsJonggi Choi, Junhwan Kim, Ju Hyun Shim, et al.
Journal of Medical Virology|February 6, 2026
Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide StudyJiwon Yang, Jihye Lim, Ye-Jee Kim, et al.
Annals of Hepatology|April 21, 2017
Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted AnalysisRoongruedee Chaiteerakij, Piyanat Chattieng, Jonggi Choi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 25, 2025
Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil FumarateJiwon Yang, Jihye Lim, Ye-Jee Kim, et al.
Journal of Korean Medical Science|April 14, 2026
Comparative Renal Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A Korean Nationwide StudyJihye Lim, Jiwon Yang, Ye-Jee Kim, et al.
JHEP Reports : Innovation in Hepatology|October 1, 2025
Incidence and risk factors of hepatocellular carcinoma in patients with autoimmune hepatitis in AsiaJiwon Yang, Sun Young Yim, Kunhee Kim, et al.
The Journal of Clinical Investigation|March 31, 2022
Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis BWon-Mook Choi, Gi-Ae Kim, Jonggi Choi, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2020
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patientsGi-Ae Kim, Seungbong Han, Gwang Hyeon Choi, et al.
Alimentary Pharmacology & Therapeutics|May 29, 2019
High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevationGwang Hyeon Choi, Gi-Ae Kim, Jonggi Choi, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
Journal of Hepatology|June 1, 2022
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resectionSun Yoo, Ji Yoon Kim, Young-Suk Lim, et al.
Journal of Cardiovascular Pharmacology|October 10, 2017
Risks Versus Benefits of Anticoagulation for Atrial Fibrillation in Cirrhotic PatientsJonggi Choi, Junhwan Kim, Ju Hyun Shim, et al.
Journal of Medical Virology|February 6, 2026
Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide StudyJiwon Yang, Jihye Lim, Ye-Jee Kim, et al.
Annals of Hepatology|April 21, 2017
Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted AnalysisRoongruedee Chaiteerakij, Piyanat Chattieng, Jonggi Choi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 25, 2025
Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil FumarateJiwon Yang, Jihye Lim, Ye-Jee Kim, et al.
Journal of Korean Medical Science|April 14, 2026
Comparative Renal Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A Korean Nationwide StudyJihye Lim, Jiwon Yang, Ye-Jee Kim, et al.
JHEP Reports : Innovation in Hepatology|October 1, 2025
Incidence and risk factors of hepatocellular carcinoma in patients with autoimmune hepatitis in AsiaJiwon Yang, Sun Young Yim, Kunhee Kim, et al.
The Journal of Clinical Investigation|March 31, 2022
Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis BWon-Mook Choi, Gi-Ae Kim, Jonggi Choi, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2020
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patientsGi-Ae Kim, Seungbong Han, Gwang Hyeon Choi, et al.
Alimentary Pharmacology & Therapeutics|May 29, 2019
High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevationGwang Hyeon Choi, Gi-Ae Kim, Jonggi Choi, et al.
Pageof 14